{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:48:23Z","timestamp":1787849303229,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12325-023-02759-9","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T19:01:58Z","timestamp":1708801318000},"page":"1594-1605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct02652494","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Juul M. P. A.","family":"van den Reek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J. T.","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-353X","authenticated-orcid":false,"given":"Sarah E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruud","family":"Prevoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margreet E.","family":"Plantenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"Elke M. G. J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"2759_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.","journal-title":"BMJ"},{"key":"2759_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","volume":"70","author":"MG Lebwohl","year":"2014","unstructured":"Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871\u201381.","journal-title":"J Am Acad Dermatol"},{"key":"2759_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2340\/00015555-0770","volume":"90","author":"M Augustin","year":"2010","unstructured":"Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol. 2010;90:147\u201351.","journal-title":"Acta Derm Venereol"},{"key":"2759_CR4","doi-asserted-by":"publisher","first-page":"adv00020","DOI":"10.2340\/00015555-3375","volume":"100","author":"CE Kleyn","year":"2020","unstructured":"Kleyn CE, Talbot PS, Mehta NN, et al. Psoriasis and mental health workshop report: exploring the links between psychosocial factors, psoriasis, neuroinflammation and cardiovascular disease risk. Acta Derm Venereol. 2020;100:adv00020.","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 2","key":"2759_CR5","first-page":"ii18","volume":"64","author":"RG Langley","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-23 (discussion ii4-5).","journal-title":"Ann Rheum Dis"},{"key":"2759_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80:251-65.e19.","journal-title":"J Am Acad Dermatol"},{"key":"2759_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2340\/00015555-1273","volume":"92","author":"F Sampogna","year":"2012","unstructured":"Sampogna F, Tabolli S, Abeni D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92:299\u2013303.","journal-title":"Acta Derm Venereol"},{"key":"2759_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","volume":"303","author":"U Mrowietz","year":"2011","unstructured":"Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1\u201310.","journal-title":"Arch Dermatol Res"},{"key":"2759_CR9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/jdv.14832","volume":"23","author":"E Papadavid","year":"2018","unstructured":"Papadavid E, Rompoti N, Theodoropoulos K, Kokkalis G, Rigopoulos D. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;23:1173\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2759_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/09546634.2018.1525480","volume":"30","author":"C Ohata","year":"2019","unstructured":"Ohata C, Ohyama B, Kuwahara F, Katayama E, Nakama T. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis. J Dermatolog Treat. 2019;30:383\u20136.","journal-title":"J Dermatolog Treat"},{"key":"2759_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4103\/idoj.IDOJ_169_19","volume":"11","author":"BJ Shah","year":"2020","unstructured":"Shah BJ, Mistry D, Chaudhary N, Shah S. Real-world efficacy and safety of apremilast monotherapy in the management of moderate-to-severe psoriasis. Indian Dermatol Online J. 2020;11:51\u20137.","journal-title":"Indian Dermatol Online J"},{"key":"2759_CR12","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1111\/jdv.16439","volume":"34","author":"E Del Alc\u00e1zar","year":"2020","unstructured":"Del Alc\u00e1zar E, Su\u00e1rez-P\u00e9rez JA, Armesto S, et al. Real-world effectiveness and safety of apremilast in psoriasis at 52\u00a0weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. J Eur Acad Dermatol Venereol. 2020;34:2821\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2759_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/jdv.16431","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Kleyn CE, Conrad C, et al. Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study. J Eur Acad Dermatol Venereol. 2021;35:123\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2759_CR14","doi-asserted-by":"crossref","unstructured":"Reich K, Korge B, Magnolo N, et al. Quality-of-life outcomes, effectiveness and tolerability of apremilast in patients with plaque psoriasis and routine German dermatology care: results from LAPIS-PSO. Dermatol Ther. 2022;12(1):203\u201321.","DOI":"10.1007\/s13555-021-00658-x"},{"key":"2759_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1007\/s12325-021-01981-7","volume":"39","author":"PD Ghislain","year":"2022","unstructured":"Ghislain PD, Lambert J, Hoai XL, et al. Real-life effectiveness of apremilast for the treatment of psoriasis in Belgium: results from the observational OTELO study. Adv Ther. 2022;39:1068\u201380.","journal-title":"Adv Ther"},{"key":"2759_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s13555-021-00628-3","volume":"12","author":"TM Klein","year":"2022","unstructured":"Klein TM, Blome C, Kleyn CE, et al. Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study. Dermatol Ther. 2022;12:81\u201395.","journal-title":"Dermatol Ther"},{"key":"2759_CR17","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1111\/jdv.18166","volume":"36","author":"D Ioannides","year":"2022","unstructured":"Ioannides D, Antonakopoulos N, Chasapi V, et al. A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-na\u00efve adults with moderate plaque psoriasis treated in the routine care in Greece\u2014the \u2018APRAISAL\u2019 study. J Eur Acad Dermatol Venereol. 2022;36:2055\u201363.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2759_CR18","unstructured":"Otezla [summary of product characteristics]. Breda, the Netherlands: Amgen Europe B.V.; July 21, 2020."},{"key":"2759_CR19","unstructured":"Volume 9A of The Rules Governing Medicinal Products in the European Union. Guidelines on Pharmacovigilance for Medicinal Products for Human Use: European Commission; 2008 [September 2008]. https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-9_en#:~:text=Volume%209%20of%20%22The%20rules,both%20human%20and%20veterinary%20use. Accessed 15 Dec 2023."},{"key":"2759_CR20","unstructured":"Foundation for the Code for Pharmaceutical Advertising Code of Conduct for Pharmaceutical Advertising: The Foundation for the Code for Pharmaceutical Advertising; 2019 [1 July 2019]. https:\/\/www.cgr.nl\/en-GB\/Gedragscode-Geneesmiddelenreclame\/Code. Accessed 15 Dec 2023."},{"key":"2759_CR21","first-page":"997","volume":"159","author":"MK Basra","year":"2008","unstructured":"Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994\u20132007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997\u20131035.","journal-title":"Br J Dermatol"},{"key":"2759_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337\u201343.","journal-title":"Ann Med"},{"key":"2759_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"2759_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00403-009-0928-8","volume":"301","author":"M Augustin","year":"2009","unstructured":"Augustin M, Radtke MA, Zschocke I, et al. The patient benefit index: a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res. 2009;301:561\u201371.","journal-title":"Arch Dermatol Res"},{"key":"2759_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00403-012-1256-y","volume":"304","author":"J Feuerhahn","year":"2012","unstructured":"Feuerhahn J, Blome C, Radtke M, Augustin M. Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis. Arch Dermatol Res. 2012;304:433\u201341.","journal-title":"Arch Dermatol Res"},{"key":"2759_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"2759_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM 1]). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"2759_CR28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52\u00a0weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"2759_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jdv.16966","volume":"35","author":"NM Golbari","year":"2021","unstructured":"Golbari NM, van der Walt JM, Blauvelt A, Ryan C, van de Kerkhof P, Kimball AB. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35:417\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2759_CR30","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s12325-023-02468-3","volume":"40","author":"P Cetkovsk\u00e1","year":"2023","unstructured":"Cetkovsk\u00e1 P, Dediol I, \u0160ola M, et al. Apremilast use in severe psoriasis: real-world data from Central and Eastern Europe. Adv Ther. 2023;40:1787\u2013802.","journal-title":"Adv Ther"},{"key":"2759_CR31","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1007\/s12325-023-02516-y","volume":"40","author":"C Giofr\u00e8","year":"2023","unstructured":"Giofr\u00e8 C, Fabbrocini G, Potenza C, et al. Real-world apremilast use for treatment of plaque psoriasis in Italy: patient perspective, characteristics, and clinical outcomes from the DARWIN Study. Adv Ther. 2023;40:3021\u201337.","journal-title":"Adv Ther"},{"key":"2759_CR32","doi-asserted-by":"publisher","first-page":"204062232311527","DOI":"10.1177\/20406223231152785","volume":"14","author":"C Jonak","year":"2023","unstructured":"Jonak C, G\u00f6ttfried I, Perl-Convalexius S, et al. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria\u2014results the APPRECIATE study. Ther Adv Chronic Dis. 2023;14:20406223231152784.","journal-title":"Ther Adv Chronic Dis"},{"key":"2759_CR33","doi-asserted-by":"crossref","unstructured":"Mease PJ, Hatemi G, Paris M, et al. Apremilast long-term safety up to 5\u00a0years from 15 pooled randomized, placebo-controlled studies of psoriasis, psoriatic arthritis, and Beh\u00e7et's syndrome. Am J Clin Dermatol. 2023;24(5):809\u201320.","DOI":"10.1007\/s40257-023-00783-7"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02759-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T09:35:58Z","timestamp":1711186558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02759-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["2759"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02759-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Juul M.P.A. van den Reek: Carried out clinical trials for AbbVie, Celgene, Almirall, and Janssen; has received speaking fees\/attended advisory boards from AbbVie, Janssen, Bristol Myers Squibb, Almirall, LEO Pharma, Novartis, UCB, and Eli Lilly; received reimbursement for attending or chairing a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre (Radboudumc) Nijmegen, the Netherlands. Robert J.T. van der Leest: Nothing to disclose. Sarah E. Thomas: Carries out clinical trials for Janssen and Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre (Radboudumc) Nijmegen, the Netherlands. Ruud Prevoo: Nothing to disclose. Margreet E. Plantenga: Employee of and stockholder in Amgen B.V. Elke M.G.J. de Jong: Received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from AbbVie, Bristol Myers Squibb, Janssen Pharmaceutica, LEO Pharma, Lilly, Novartis, and UCB; ZonMw, KCE, NWO, the National Psoriasis Foundation USA, RUMC\/VGZ and RUMC\/SMK. Has been a consultant, paid speaker, and\/or participated in research for AbbVie, Amgen, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, LEO Pharma, Sanofi, and UCB. All funding is not personal but goes to the Radboud University Medical Centre (Radboudumc), Nijmegen, the Netherlands.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Code Geneesmiddelenreclame (CGR) and performed in accordance with Volume 9A of the Rules Governing Medicinal Products in the European Union, the Gedragscode Geneesmiddelenreclame of the CGR, and good pharmacovigilance practice. The study was approved by a national central ethics committee for observational studies in the Netherlands. nWMO statement given by the Regionale Toetsingscommissie Pati\u00ebntgebonden Onderzoek (RTPO) located in Leeuwarden, Netherlands, Ref. no. RTPO 959. Dutch Clinical Research Foundation (DCRF) \u00a0 METC* 2015\u2013119. All patients provided written informed consent before study initiation. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}